“the golden age?”
CLINUVEL Non-Executive Chair Brenda Shanahan and Non-Executive Director Roger Aston discuss the progress of CLINUVEL’s clinical program with Scenesse® (Afamelanotide)
Administered by physicians as a controlled-release resorbable implant, Scenesse® is a preventative drug activating melanin – pigmentation – in the skin.
Melanin provides a biological barrier, protecting skin from UV and visible light. Medically, this is known as photoprotection.
Scenesse® is released over 10 days by the implant, while activating melanin for up to 60 days. The breakthrough controlled-release formulation maximizes the effect of the drug, while minimizing patient exposure to drug substance.
CLINUVEL’s ongoing clinical program aims to demonstrate the safety and efficacy of Scenesse® as a medicinal photoprotective drug.